DE69926254D1 - Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden - Google Patents
Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptidenInfo
- Publication number
- DE69926254D1 DE69926254D1 DE69926254T DE69926254T DE69926254D1 DE 69926254 D1 DE69926254 D1 DE 69926254D1 DE 69926254 T DE69926254 T DE 69926254T DE 69926254 T DE69926254 T DE 69926254T DE 69926254 D1 DE69926254 D1 DE 69926254D1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- inhibitors
- radioligands
- preparation
- amyloid peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 3
- 239000002287 radioligand Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10814798P | 1998-11-12 | 1998-11-12 | |
| US13128499P | 1999-04-27 | 1999-04-27 | |
| PCT/US1999/026715 WO2000028331A1 (en) | 1998-11-12 | 1999-11-12 | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69926254D1 true DE69926254D1 (de) | 2005-08-25 |
Family
ID=26805566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69926254T Expired - Lifetime DE69926254D1 (de) | 1998-11-12 | 1999-11-12 | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6331408B1 (de) |
| EP (1) | EP1129355B1 (de) |
| AT (1) | ATE300052T1 (de) |
| AU (1) | AU1618000A (de) |
| CA (1) | CA2346099A1 (de) |
| DE (1) | DE69926254D1 (de) |
| NO (1) | NO20011891L (de) |
| WO (1) | WO2000028331A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ509241A (en) | 1998-08-07 | 2003-08-29 | Du Pont Pharm Co | Succinoylamino lactams as inhibitors of alpha-beta protein production |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| US6737038B1 (en) * | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| US6331408B1 (en) * | 1998-11-12 | 2001-12-18 | Robert Zaczek | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production |
| AU778005B2 (en) | 1998-12-24 | 2004-11-11 | Bristol-Myers Squibb Pharma Company | Succinoylamino benzodiazepines as inhibitors of Abeta protein production |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| JP2003523345A (ja) | 2000-02-17 | 2003-08-05 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Aβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環 |
| JP2004508289A (ja) | 2000-04-03 | 2004-03-18 | デュポン ファーマシューティカルズ カンパニー | Aβタンパク質産生の阻害剤としての環状ラクタム |
| MXPA02009755A (es) | 2000-04-03 | 2003-03-27 | Bristol Myers Squibb Pharma Co | Lactamas ciclicas como inhibidores de la produccion de proteina a-beta. |
| US6878363B2 (en) * | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| WO2001092235A1 (en) * | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| EP1379634B1 (de) * | 2001-04-20 | 2017-12-13 | The University Of Georgia Research Foundation, Inc. | Inaktivatoren aktiver zentren |
| US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| EP2261254A3 (de) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Antiamyloide Antikörper und deren Verwendungen |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
| US9242941B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
| JP2015529253A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Notch阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル1,4−ベンゾジアゼピノン化合物 |
| JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 1,4−ベンゾジアゼピノン化合物のプロドラッグ |
| EP2897946B1 (de) | 2012-09-21 | 2016-11-16 | Bristol-Myers Squibb Company | N-substituierte bis(fluoralkyl)-1,4-benzodiazepinonverbindungen |
| JP2015529251A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Notch阻害剤としての三環系複素環式化合物 |
| US9133126B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzoazepinone compounds |
| JP2015534553A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換1,5−ベンゾジアゼピノン化合物 |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
| CN105101968A (zh) | 2013-04-04 | 2015-11-25 | 百时美施贵宝公司 | 治疗增殖性疾病的组合疗法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
| US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
| GB9022117D0 (en) * | 1990-10-11 | 1990-11-21 | Beecham Group Plc | Novel compounds |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5538845A (en) * | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| WO1994026723A2 (en) * | 1993-05-14 | 1994-11-24 | Genentech, Inc. | ras FARNESYL TRANSFERASE INHIBITORS |
| CZ184194A3 (en) * | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
| US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| AU4589297A (en) * | 1996-10-07 | 1998-05-05 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
| US5734054A (en) * | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
| US6331408B1 (en) * | 1998-11-12 | 2001-12-18 | Robert Zaczek | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production |
-
1999
- 1999-11-12 US US09/438,901 patent/US6331408B1/en not_active Expired - Lifetime
- 1999-11-12 CA CA002346099A patent/CA2346099A1/en not_active Abandoned
- 1999-11-12 AT AT99958905T patent/ATE300052T1/de not_active IP Right Cessation
- 1999-11-12 AU AU16180/00A patent/AU1618000A/en not_active Abandoned
- 1999-11-12 EP EP99958905A patent/EP1129355B1/de not_active Expired - Lifetime
- 1999-11-12 WO PCT/US1999/026715 patent/WO2000028331A1/en not_active Ceased
- 1999-11-12 DE DE69926254T patent/DE69926254D1/de not_active Expired - Lifetime
-
2001
- 2001-04-17 NO NO20011891A patent/NO20011891L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000028331A1 (en) | 2000-05-18 |
| EP1129355A1 (de) | 2001-09-05 |
| NO20011891D0 (no) | 2001-04-17 |
| ATE300052T1 (de) | 2005-08-15 |
| NO20011891L (no) | 2001-07-02 |
| CA2346099A1 (en) | 2000-05-18 |
| US6331408B1 (en) | 2001-12-18 |
| AU1618000A (en) | 2000-05-29 |
| EP1129355B1 (de) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69926254D1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
| ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| ATE239797T1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
| MY131442A (en) | Excitatory amino acid receptor antagonists | |
| ATE491721T1 (de) | Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten | |
| EA200401365A1 (ru) | Способы лечения илеуса | |
| WO2003104418A3 (en) | Reconstituted polypeptides | |
| WO2001087354A3 (en) | Use of small molecule radioligands for diagnostic imaging | |
| NO20006645D0 (no) | Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme | |
| DK0474767T3 (da) | Dopaminagonister | |
| DE69530933D1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
| ATE196083T1 (de) | Verwendung von ferrioxamin-b zur behandlung septischen schocks | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
| DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| NO975961L (no) | Fremgangsmåte for fremstilling av 1-(3-trialkylsilylfenyl)-2,2,2-trifluorometyl-ethanonderivater | |
| WO2003045325A3 (en) | Dopaminergic stimulatory factor | |
| DE60235161D1 (de) | Methoden und zusammensetzungen zur identifikation von gen-funktion | |
| WO1999006838A3 (en) | Novel method of detecting amyloid-like fibrils or protein aggregates | |
| ATE420637T1 (de) | Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |